Skip to content
Clinical Trials – home
HungaryBack to Hungary

Clinical trials in Szombathely – page 2

173 clinical trials in Szombathely, Hungary across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Szombathely at a glance
173
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

173 trials in Szombathely

Open in trial search

Cardiac failure

Recruiting

Study on BI 690517 and Empagliflozin for Patients with Heart Failure and Preserved Ejection Fraction

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim International GmbH

Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Selatogrel
  • Sponsor:Viatris Innovation GmbH

Study on Long-Term Safety of Ianalumab for Patients with Systemic Lupus Erythematosus

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

Study on the Long-term Safety and Efficacy of Pembrolizumab and Lenvatinib for Patients with Advanced Tumors

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab
  • Sponsor:Merck Sharp & Dohme LLC

Neutropenia

Recruiting

Study on Mavorixafor for Patients with Chronic Neutropenia Experiencing Recurrent or Serious Infections

Investigational
Countries:HungaryHungary
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Mavorixafor
  • Sponsor:X4 Pharmaceuticals Inc.

Obesity

Recruiting

Long‑term Efficacy, Safety and Tolerability of maridebart cafraglutide in Adults with Obesity and Type 2 Diabetes

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

A study of the safety and efficacy of AC01 in patients with heart failure with reduced ejection fraction

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Drocamorelin
  • Sponsor:AnaCardio AB

A Phase 2/3 Randomized Double‑Blind Study of Inebilizumab for Safety and Tolerability in Patients with Autoimmune Hepatitis

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Inebilizumab
  • Sponsor:Amgen Inc.

Efficacy and safety of ABP 938 compared with aflibercept in participants with neovascular age‑related macular degeneration

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Amgen Inc.

Effect of elecoglipron plus dapagliflozin on cardiovascular outcomes in adults with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF)

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:Astrazeneca AB

Efficacy and safety of lunsekimig in adults with inadequately controlled eosinophilic COPD: a randomized, double‑blind, placebo‑controlled trial

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Lunsekimig
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Gastric cancer+1

Recruiting

Study of AZD0901 (sonesitatug vedotin) with capecitabine ± rilvegostomig in adults with advanced stomach or esophageal cancer (Claudin‑18.2‑positive, HER2‑negative)

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:AZD0901
  • Sponsor:Astrazeneca AB

Other cities in Hungary

The busiest research cities in the country

All 73 cities in Hungary

Clinical research in Szombathely

What the registry says about research in the country

01 Respiratory Medicine

Clinical trials focusing on respiratory conditions, particularly investigating new treatments for asthma and COPD. Studies evaluate innovative therapies including atuliflapon and dupilumab for improving lung function and disease control.

  • Moderate to severe asthma management
  • COPD treatment optimization
  • Lung function preservation

Research aims to enhance therapeutic options for patients with uncontrolled respiratory conditions.

02 Dermatology & Immunology

Innovative research in inflammatory skin conditions and immune-mediated disorders, including studies on atopic dermatitis, plaque psoriasis, and hidradenitis suppurativa.

  • Advanced biologics evaluation
  • Inflammatory disease management
  • Novel therapeutic approaches

Studies focus on developing targeted treatments for chronic inflammatory conditions.

03 Oncology & Hematology

Groundbreaking research in cancer treatment and blood disorders, including studies on breast cancer, lymphoma, and multiple myeloma. Investigations of targeted therapies and combination treatments.

  • Breast cancer therapy
  • Lymphoma treatment
  • Multiple myeloma management

Focus on improving survival rates and treatment outcomes in various cancer types.

04 Gastroenterology

Clinical research examining treatments for inflammatory bowel diseases, including studies on Crohn's Disease and Ulcerative Colitis. Evaluation of combination therapies and novel biological agents.

  • IBD treatment advancement
  • Combination therapy assessment
  • Disease control optimization

Emphasis on improving quality of life for patients with chronic digestive conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.